Cytisinicline - Achieve Life Sciences
Alternative Names: Cytisine; Cytisine-Achieve-Life-Sciences; Desmoxan; TabexLatest Information Update: 11 Dec 2024
Price :
$50 *
At a glance
- Originator Sopharma
- Developer Achieve Life Sciences
- Class 2 ring heterocyclic compounds; Alkaloids; Pyridones; Small molecules; Smoking cessation therapies
- Mechanism of Action Alpha4 beta2 nicotinic receptor agonists; Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Smoking withdrawal
Most Recent Events
- 03 Dec 2024 Achieve Life Sciences plans a phase III ORCA-V2 trial for Smoking withdrawal in the third quarter of 2025
- 28 Nov 2024 No recent reports of development identified for phase-I development in Smoking-withdrawal(In volunteers) in Portugal (PO, Tablet)
- 10 Oct 2024 Achieve Life Sciences completes enrolment in the phase III ORCA-OL trial for Smoking withdrawal in USA (NCT06435221)